{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:46:07Z","timestamp":1791211567154,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04050-5","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T13:22:19Z","timestamp":1727184139000},"page":"875-890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus"],"prefix":"10.1007","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6549-9002","authenticated-orcid":false,"given":"Eleni-Rafaela","family":"Kani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2938-0889","authenticated-orcid":false,"given":"Eleftheria","family":"Karaviti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2220-1152","authenticated-orcid":false,"given":"Dimitra","family":"Karaviti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4539-8319","authenticated-orcid":false,"given":"Eleni","family":"Gerontiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Saltiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Stefanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Psaltopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"issue":"1","key":"4050_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s13340-018-0362-2","volume":"10","author":"MY Baden","year":"2019","unstructured":"M.Y. Baden, A. Imagawa, N. Abiru, T. Awata, H. Ikegami, Y. Uchigata, Y. Oikawa, H. Osawa, H. Kajio, E. Kawasaki, Y. Kawabata, J. Kozawa, A. Shimada, K. Takahashi, S. Tanaka, D. Chujo, T. Fukui, J. Miura, K. Yasuda; consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research, Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol. Int. 10(1), 58\u201366 (2019). https:\/\/doi.org\/10.1007\/s13340-018-0362-2","journal-title":"Diabetol. Int."},{"issue":"4","key":"4050_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"E.P. Darnell, M.J. Mooradian, E.N. Baruch, M. Yilmaz, K.L. Reynolds, Immune-Related Adverse Events (irAEs): diagnosis, management, and clinical pearls. Curr. Oncol. Rep. 22(4), 39 (2020). https:\/\/doi.org\/10.1007\/s11912-020-0897-9","journal-title":"Curr. Oncol. Rep."},{"issue":"26","key":"4050_CR3","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"J.R. Brahmer, S.S. Tykodi, L.Q.M. Chow, W.-J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, H.C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T.M. Salay, S. Alaparthy, J.F. Grosso, J.M. Wigginton, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455\u20132465 (2012). https:\/\/doi.org\/10.1056\/NEJMoa1200694","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"4050_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3366","volume":"37","author":"Z Zheng","year":"2021","unstructured":"Z. Zheng, Y. Liu, J. Yang, C. Tan, L. Zhou, X. Wang, L. Xiao, S. Zhang, Y. Chen, X. Liu, Diabetes mellitus induced by immune checkpoint inhibitors. Diab. Metab. Res. Rev. 37(1), e3366 (2021). https:\/\/doi.org\/10.1002\/dmrr.3366","journal-title":"Diab. Metab. Res. Rev."},{"key":"4050_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110414","volume":"122","author":"D Liao","year":"2023","unstructured":"D. Liao, C. Liu, S. Chen, F. Liu, W. Li, D. Shangguan, Y. Shi, Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus. Int. Immunopharmacol. 122, 110414 (2023). https:\/\/doi.org\/10.1016\/j.intimp.2023.110414","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"4050_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-19-0291","volume":"181","author":"JMK de Filette","year":"2019","unstructured":"J.M.K. de Filette, J.J. Pen, L. Decoster, T. Vissers, B. Bravenboer, B.J. Van der Auwera, F.K. Gorus, B.O. Roep, S. Aspeslagh, B. Neyns, B. Velkeniers, A.V. Kharagjitsingh, Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review. Eur. J. Endocrinol. 181(3), 363\u2013374 (2019). https:\/\/doi.org\/10.1530\/EJE-19-0291","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"4050_CR7","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.2337\/dc18-2518","volume":"42","author":"S Yoneda","year":"2019","unstructured":"S. Yoneda, A. Imagawa, Y. Hosokawa, M.Y. Baden, T. Kimura, S. Uno, K. Fukui, K. Goto, M. Uemura, H. Eguchi, H. Iwahashi, J. Kozawa, I. Shimomura, T-lymphocyte infiltration to islets in the pancreas of a patient who developed type 1 diabetes after administration of immune checkpoint inhibitors. Diab. Care 42(7), e116\u2013e118 (2019). https:\/\/doi.org\/10.2337\/dc18-2518","journal-title":"Diab. Care"},{"issue":"33","key":"4050_CR8","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1073\/pnas.0505497102","volume":"102","author":"J Wang","year":"2005","unstructured":"J. Wang, T. Yoshida, F. Nakaki, H. Hiai, T. Okazaki, T. Honjo, Establishment of NOD-Pdcd1-\/- mice as an efficient animal model of type I diabetes. Proc. Natl Acad. Sci. USA 102(33), 11823\u201311828 (2005). https:\/\/doi.org\/10.1073\/pnas.0505497102","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"6","key":"4050_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1046\/j.1399-0039.2003.00136.x","volume":"62","author":"C Nielsen","year":"2003","unstructured":"C. Nielsen, D. Hansen, S. Husby, B.B. Jacobsen, S.T. Lillevang, Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62(6), 492\u2013497 (2003). https:\/\/doi.org\/10.1046\/j.1399-0039.2003.00136.x","journal-title":"Tissue Antigens"},{"issue":"10","key":"4050_CR10","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","volume":"10","author":"H Nishimura","year":"1998","unstructured":"H. Nishimura, N. Minato, T. Nakano, T. Honjo, Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10(10), 1563\u20131572 (1998). https:\/\/doi.org\/10.1093\/intimm\/10.10.1563","journal-title":"Int. Immunol."},{"issue":"3","key":"4050_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1122","volume":"9","author":"J Lu","year":"2020","unstructured":"J. Lu, J. Liu, L. Li, Y. Lan, Y. Liang, Cytokines in type 1 diabetes: Mechanisms of action and immunotherapeutic targets. Clin. Transl. Immunol. 9(3), e1122 (2020). https:\/\/doi.org\/10.1002\/cti2.1122","journal-title":"Clin. Transl. Immunol."},{"issue":"1","key":"4050_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3803\/EnM.2021.1282","volume":"37","author":"H Inaba","year":"2022","unstructured":"H. Inaba, Y. Kaido, S. Ito, T. Hirobata, G. Inoue, T. Sugita, Y. Yamamoto, M. Jinnin, H. Kimura, T. Kobayashi, S. Iwama, H. Arima, T. Matsuoka, Human leukocyte antigens and biomarkers in type 1 diabetes mellitus induced by immune-checkpoint inhibitors. Endocrinol. Metab. 37(1), 84\u201395 (2022). https:\/\/doi.org\/10.3803\/EnM.2021.1282","journal-title":"Endocrinol. Metab."},{"issue":"8","key":"4050_CR13","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"A.M. Stamatouli, Z. Quandt, A.L. Perdigoto, P.L. Clark, H. Kluger, S.A. Weiss, S. Gettinger, M. Sznol, A. Young, R. Rushakoff, J. Lee, J.A. Bluestone, M. Anderson, K.C. Herold, Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67(8), 1471\u20131480 (2018). https:\/\/doi.org\/10.2337\/dbi18-0002","journal-title":"Diabetes"},{"issue":"2","key":"4050_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/cei.13424","volume":"200","author":"Z Quandt","year":"2020","unstructured":"Z. Quandt, A. Young, M. Anderson, Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin. Exp. Immunol. 200(2), 131\u2013140 (2020). https:\/\/doi.org\/10.1111\/cei.13424","journal-title":"Clin. Exp. Immunol."},{"issue":"11","key":"4050_CR15","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.1210\/jc.2019-00423","volume":"104","author":"VHM Tsang","year":"2019","unstructured":"V.H.M. Tsang, R.T. McGrath, R.J. Clifton-Bligh, R.A. Scolyer, V. Jakrot, A.D. Guminski, G.V. Long, A.M. Menzies, Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes. J. Clin. Endocrinol. Metab. 104(11), 5499\u20135506 (2019). https:\/\/doi.org\/10.1210\/jc.2019-00423","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"4050_CR16","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","volume":"22","author":"J Judd","year":"2017","unstructured":"J. Judd, M. Zibelman, E. Handorf, J. O\u2019Neill, C. Ramamurthy, S. Bentota, J. Doyle, R.G. Uzzo, J. Bauman, H. Borghaei, E.R. Plimack, R. Mehra, D.M. Geynisman, Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors. Oncologist 22(10), 1232\u20131237 (2017). https:\/\/doi.org\/10.1634\/theoncologist.2017-0133","journal-title":"Oncologist"},{"issue":"1","key":"4050_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1200\/JCO.2014.57.5688","volume":"33","author":"C Yuan","year":"2015","unstructured":"C. Yuan, D.A. Rubinson, Z.R. Qian, C. Wu, P. Kraft, Y. Bao, S. Ogino, K. Ng, T.E. Clancy, R.S. Swanson, M.J. Gorman, L.K. Brais, T. Li, M.J. Stampfer, F.B. Hu, E.L. Giovannucci, M.H. Kulke, C.S. Fuchs, B.M. Wolpin, Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 33(1), 29\u201335 (2015). https:\/\/doi.org\/10.1200\/JCO.2014.57.5688","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"4050_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5162-3","volume":"18","author":"S Akhavan","year":"2018","unstructured":"S. Akhavan, A. Ghahghaei-Nezamabadi, M. Modaresgilani, A.S. Mousavi, M. Sepidarkish, A. Tehranian, E. Rezayof, Impact of diabetes mellitus on epithelial ovarian cancer survival. BMC Cancer 18(1), 1246 (2018). https:\/\/doi.org\/10.1186\/s12885-018-5162-3","journal-title":"BMC Cancer"},{"issue":"6","key":"4050_CR19","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"E.S. Husebye, F. Castinetti, S. Criseno, G. Curigliano, B. Decallonne, M. Fleseriu, C.E. Higham, I. Lupi, S.A. Paschou, M. Toth, M. van der Kooij, O.M. Dekkers, Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An ESE clinical practice guideline. Eur. J. Endocrinol. 187(6), G1\u2013G21 (2022). https:\/\/doi.org\/10.1530\/EJE-22-0689","journal-title":"Eur. J. Endocrinol."},{"key":"4050_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1248919","volume":"14","author":"E Daetwyler","year":"2023","unstructured":"E. Daetwyler, A. Zippelius, S. Danioth, M.Y. Donath, L. Gut, Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options. Front. Immunol. 14, 1248919 (2023). https:\/\/doi.org\/10.3389\/fimmu.2023.1248919","journal-title":"Front. Immunol."},{"issue":"3","key":"4050_CR21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1159\/000480634","volume":"10","author":"J Kapke","year":"2017","unstructured":"J. Kapke, Z. Shaheen, D. Kilari, P. Knudson, S. Wong, Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management. Case Rep. Oncol. 10(3), 897\u2013909 (2017). https:\/\/doi.org\/10.1159\/000480634","journal-title":"Case Rep. Oncol."},{"issue":"suppl_4","key":"4050_CR22","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"JBaG Haanen","year":"2017","unstructured":"J.Ba.G. Haanen, F. Carbonnel, C. Robert, K.M. Kerr, S. Peters, J. Larkin, K. Jordan; ESMO Guidelines Committee, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 28(suppl_4), iv119\u2013iv142 (2017). https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"36","key":"4050_CR23","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"B.J. Schneider, J. Naidoo, B.D. Santomasso, C. Lacchetti, S. Adkins, M. Anadkat, M.B. Atkins, K.J. Brassil, J.M. Caterino, I. Chau, M.J. Davies, M.S. Ernstoff, L. Fecher, M. Ghosh, I. Jaiyesimi, J.S. Mammen, A. Naing, L.J. Nastoupil, T. Phillips, K. Bollin, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 39(36), 4073\u20134126 (2021). https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"4050_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"I. Puzanov, A. Diab, K. Abdallah, C.O. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M.E. Lacouture, N.R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A.W. Silk, D. Skondra, M.E. Suarez-Almazor, Y. Wang, K. Wiley; Society for Immunotherapy of Cancer Toxicity Management Working Group, Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5(1), 95 (2017). https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"4050_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100011","volume":"6","author":"SA Paschou","year":"2021","unstructured":"S.A. Paschou, K. Stefanaki, T. Psaltopoulou, M. Liontos, K. Koutsoukos, F. Zagouri, I. Lambrinoudaki, M.-A. Dimopoulos, How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open 6(1), 100011 (2021). https:\/\/doi.org\/10.1016\/j.esmoop.2020.100011","journal-title":"ESMO Open"},{"issue":"7","key":"4050_CR26","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EC-18-0068","volume":"7","author":"CE Higham","year":"2018","unstructured":"C.E. Higham, A. Olsson-Brown, P. Carroll, T. Cooksley, J. Larkin, P. Lorigan, D. Morganstein, P.J. Trainer; Society for Endocrinology Clinical Committee, Society for Endocrinology Endocrine Emergency Guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr. Connect. 7(7), G1\u2013G7 (2018). https:\/\/doi.org\/10.1530\/EC-18-0068","journal-title":"Endocr. Connect."},{"issue":"7","key":"4050_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","volume":"66","author":"H Arima","year":"2019","unstructured":"H. Arima, S. Iwama, H. Inaba, H. Ariyasu, N. Makita, M. Otsuki, K. Kageyama, A. Imagawa, T. Akamizu, Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society. Endocr. J. 66(7), 581\u2013586 (2019). https:\/\/doi.org\/10.1507\/endocrj.EJ19-0163","journal-title":"Endocr. J."},{"issue":"5","key":"4050_CR28","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1464-5491.2011.03246.x","volume":"28","author":"MW Savage","year":"2011","unstructured":"M.W. Savage, K.K. Dhatariya, A. Kilvert, G. Rayman, Ja.E. Rees, C.H. Courtney, L. Hilton, P.H. Dyer, M.S. Hamersley; Joint British Diabetes Societies, Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet. Med.: A J. Br. Diabet. Assoc. 28(5), 508\u2013515 (2011). https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03246.x","journal-title":"Diabet. Med.: A J. Br. Diabet. Assoc."},{"issue":"3","key":"4050_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky021","volume":"2","author":"M Girotra","year":"2018","unstructured":"M. Girotra, A. Hansen, A. Farooki, D.J. Byun, L. Min, B.C. Creelan, M.K. Callahan, M.B. Atkins, E. Sharon, S.J. Antonia, P. West, A.E. Gravell, Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration, The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2(3), pky021 (2018). https:\/\/doi.org\/10.1093\/jncics\/pky021","journal-title":"JNCI Cancer Spectr."},{"issue":"2","key":"4050_CR30","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERC-18-0320","volume":"26","author":"F Castinetti","year":"2019","unstructured":"F. Castinetti, F. Albarel, F. Archambeaud, J. Bertherat, B. Bouillet, P. Buffier, C. Briet, B. Cariou, P. Caron, O. Chabre, P. Chanson, C. Cortet, C. Do Cao, D. Drui, M. Haissaguerre, S. Hescot, F. Illouz, E. Kuhn, N. Lahlou, F. Borson-Chazot, French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr.-Relat. Cancer 26(2), G1\u2013G18 (2019). https:\/\/doi.org\/10.1530\/ERC-18-0320","journal-title":"Endocr.-Relat. Cancer"},{"issue":"Suppl 1","key":"4050_CR31","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"American Diabetes Association Profe","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee, 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diab. Care 45(Suppl 1), S17\u2013S38 (2022). https:\/\/doi.org\/10.2337\/dc22-S002","journal-title":"Diab. Care"},{"key":"4050_CR32","unstructured":"National Clinical Guideline Centre (UK). (2015). Type 1 Diabetes in Adults: Diagnosis and Management. National Institute for Health and Care Excellence (NICE). http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK315808\/"},{"key":"4050_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1157805","volume":"14","author":"Z Cardona","year":"2023","unstructured":"Z. Cardona, J.A. Sosman, S. Chandra, W. Huang, Endocrine side effects of immune checkpoint inhibitors. Front. Endocrinol. 14, 1157805 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1157805","journal-title":"Front. Endocrinol."},{"issue":"1","key":"4050_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/157339913804143199","volume":"9","author":"A Jervis","year":"2013","unstructured":"A. Jervis, S. Champion, G. Figg, J. Langley, G.G. Adams, Prevalence of diabetes ketoacidosis rises and still no strict treatment adherence. Curr. Diab. Rev. 9(1), 54\u201361 (2013)","journal-title":"Curr. Diab. Rev."},{"issue":"1","key":"4050_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2337\/diacare.3.1.15","volume":"3","author":"GA Burghen","year":"1980","unstructured":"G.A. Burghen, J.N. Etteldorf, J.N. Fisher, A.Q. Kitabchi, Comparison of high-dose and low-dose insulin by continuous intravenous infusion in the treatment of diabetic ketoacidosis in children. Diab. Care 3(1), 15\u201320 (1980). https:\/\/doi.org\/10.2337\/diacare.3.1.15","journal-title":"Diab. Care"},{"issue":"7","key":"4050_CR36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00134-007-0674-3","volume":"33","author":"V Shankar","year":"2007","unstructured":"V. Shankar, A. Haque, K.B. Churchwell, W. Russell, Insulin glargine supplementation during early management phase of diabetic ketoacidosis in children. Intensive Care Med. 33(7), 1173\u20131178 (2007). https:\/\/doi.org\/10.1007\/s00134-007-0674-3","journal-title":"Intensive Care Med."},{"issue":"4","key":"4050_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jemermed.2007.11.033","volume":"38","author":"N Goyal","year":"2010","unstructured":"N. Goyal, J.B. Miller, S.S. Sankey, U. Mossallam, Utility of initial bolus insulin in the treatment of diabetic ketoacidosis. J. Emerg. Med. 38(4), 422\u2013427 (2010). https:\/\/doi.org\/10.1016\/j.jemermed.2007.11.033","journal-title":"J. Emerg. Med."},{"issue":"7","key":"4050_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"J.J. Wright, A.C. Powers, D.B. Johnson, Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 17(7), 389\u2013399 (2021). https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"4050_CR39","doi-asserted-by":"publisher","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","volume":"7","author":"A Kotwal","year":"2019","unstructured":"A. Kotwal, C. Haddox, M. Block, Y.C. Kudva, Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diab. Res. Care 7(1), e000591 (2019). https:\/\/doi.org\/10.1136\/bmjdrc-2018-000591","journal-title":"BMJ Open Diab. Res. Care"},{"issue":"6","key":"4050_CR40","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"R. Barroso-Sousa, P.A. Ott, F.S. Hodi, U.B. Kaiser, S.M. Tolaney, L. Min, Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer 124(6), 1111\u20131121 (2018). https:\/\/doi.org\/10.1002\/cncr.31200","journal-title":"Cancer"},{"issue":"1","key":"4050_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26471-9","volume":"8","author":"KC Osum","year":"2018","unstructured":"K.C. Osum, A.L. Burrack, T. Martinov, N.L. Sahli, J.S. Mitchell, C.G. Tucker, K.E. Pauken, K. Papas, B. Appakalai, J.A. Spanier, B.T. Fife, Interferon-gamma drives programmed death-ligand 1 expression on islet \u03b2 cells to limit T cell function during autoimmune diabetes. Sci. Rep. 8(1), 8295 (2018). https:\/\/doi.org\/10.1038\/s41598-018-26471-9","journal-title":"Sci. Rep."},{"issue":"9","key":"4050_CR42","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2018-00728","volume":"103","author":"K Clotman","year":"2018","unstructured":"K. Clotman, K. Janssens, P. Specenier, I. Weets, C.E.M. De Block, Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 103(9), 3144\u20133154 (2018). https:\/\/doi.org\/10.1210\/jc.2018-00728","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"4050_CR43","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","volume":"66","author":"M-L Gauci","year":"2017","unstructured":"M.-L. Gauci, P. Laly, T. Vidal-Trecan, B. Baroudjian, J. Gottlieb, N. Madjlessi-Ezra, L. Da Meda, I. Madelaine-Chambrin, M. Bagot, N. Basset-Seguin, C. Pages, S. Mourah, P. Boudou, C. Lebb\u00e9, J.-F. Gautier, Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol., Immunotherapy: CII 66(11), 1399\u20131410 (2017). https:\/\/doi.org\/10.1007\/s00262-017-2033-8","journal-title":"Cancer Immunol., Immunotherapy: CII"},{"issue":"11","key":"4050_CR44","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.autrev.2013.05.003","volume":"12","author":"E Gianchecchi","year":"2013","unstructured":"E. Gianchecchi, D.V. Delfino, A. Fierabracci, Recent insights into the role of the PD-1\/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun. Rev. 12(11), 1091\u20131100 (2013). https:\/\/doi.org\/10.1016\/j.autrev.2013.05.003","journal-title":"Autoimmun. Rev."},{"key":"4050_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0196-z","volume":"4","author":"JR Lowe","year":"2016","unstructured":"J.R. Lowe, D.J. Perry, A.K.S. Salama, C.E. Mathews, L.G. Moss, B.A. Hanks, Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J. Immunother. Cancer 4, 89 (2016). https:\/\/doi.org\/10.1186\/s40425-016-0196-z","journal-title":"J. Immunother. Cancer"},{"issue":"21","key":"4050_CR46","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1097\/CM9.0000000000000972","volume":"133","author":"R Zhang","year":"2020","unstructured":"R. Zhang, X.-L. Cai, L. Liu, X.-Y. Han, L.-N. Ji, Type 1 diabetes induced by immune checkpoint inhibitors. Chin. Med. J. 133(21), 2595\u20132598 (2020). https:\/\/doi.org\/10.1097\/CM9.0000000000000972","journal-title":"Chin. Med. J."},{"issue":"6","key":"4050_CR47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.therap.2021.03.004","volume":"76","author":"M Bastin","year":"2021","unstructured":"M. Bastin, M. Allouchery, M. Sassier, F. Rouby, P. Eftekhari, B. Lebrun-Vignes, F. Andreelli, K. Bihan, Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: a French pharmacovigilance study. Therapie 76(6), 695\u2013703 (2021). https:\/\/doi.org\/10.1016\/j.therap.2021.03.004","journal-title":"Therapie"},{"issue":"12","key":"4050_CR48","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.2337\/dc18-1465","volume":"41","author":"JJ Wright","year":"2018","unstructured":"J.J. Wright, J.-E. Salem, D.B. Johnson, B. Lebrun-Vignes, A. Stamatouli, J.W. Thomas, K.C. Herold, J. Moslehi, A.C. Powers, Increased reporting of immune checkpoint inhibitor-associated diabetes. Diab. Care 41(12), e150\u2013e151 (2018). https:\/\/doi.org\/10.2337\/dc18-1465","journal-title":"Diab. Care"},{"issue":"2","key":"4050_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/diseases12020040","volume":"12","author":"A Angelousi","year":"2024","unstructured":"A. Angelousi, D.C. Ziogas, V. Siampanopoulou, C. Mytareli, A. Anastasopoulou, G. Lyrarakis, H. Gogas, Reaching the diagnosis of checkpoint inhibitor-induced diabetes mellitus in different clinical scenarios: a real-world application of updated diagnostic criteria. Dis. (Basel, Switz.) 12(2), 40 (2024). https:\/\/doi.org\/10.3390\/diseases12020040","journal-title":"Dis. (Basel, Switz.)"},{"key":"4050_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1369268","volume":"15","author":"L Yang","year":"2024","unstructured":"L. Yang, S. Murthy, A. Cortellini, E.A. Lim, M. Gonzalez, D.J. Pinato, M. Abdel-Malek, S. Mahmoud, N.M. Martin, Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival. Front. Endocrinol. 15, 1369268 (2024). https:\/\/doi.org\/10.3389\/fendo.2024.1369268","journal-title":"Front. Endocrinol."},{"issue":"8","key":"4050_CR51","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/2767-9764.CRC-23-0145","volume":"3","author":"VP Nguyen","year":"2023","unstructured":"V.P. Nguyen, K.M. Campbell, T.S. Nowicki, N. Elumalai, E. Medina, I. Baselga-Carretero, M.L. DiNome, H.R. Chang, D.K. Oseguera, A. Ribas, J.A. Glaspy, A pilot study of neoadjuvant nivolumab, ipilimumab, and intralesional oncolytic virotherapy for HER2-negative breast cancer. Cancer Res. Commun. 3(8), 1628\u20131637 (2023). https:\/\/doi.org\/10.1158\/2767-9764.CRC-23-0145","journal-title":"Cancer Res. Commun."},{"issue":"5","key":"4050_CR52","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/cncr.34016","volume":"128","author":"H Emamekhoo","year":"2022","unstructured":"H. Emamekhoo, M.R. Olsen, B.C. Carthon, A. Drakaki, I.J. Percent, A.M. Molina, D.C. Cho, J.C. Bendell, L.N. Gordan, A. Rezazadeh Kalebasty, D.J. George, T.E. Hutson, E.R. Arrowsmith, J. Zhang, J. Zoco, J.L. Johansen, D.K. Leung, S.S. Tykodi, Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer 128(5), 966\u2013974 (2022). https:\/\/doi.org\/10.1002\/cncr.34016","journal-title":"Cancer"},{"issue":"5","key":"4050_CR53","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00280-015-2873-x","volume":"76","author":"N Yamazaki","year":"2015","unstructured":"N. Yamazaki, Y. Kiyohara, H. Uhara, S. Fukushima, H. Uchi, N. Shibagaki, A. Tsutsumida, S. Yoshikawa, R. Okuyama, Y. Ito, T. Tokudome, Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother. Pharmacol. 76(5), 997\u20131004 (2015). https:\/\/doi.org\/10.1007\/s00280-015-2873-x","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"4050_CR54","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.clgc.2020.06.002","volume":"18","author":"JJ McFarlane","year":"2020","unstructured":"J.J. McFarlane, M.D. Kochenderfer, M.R. Olsen, T.M. Bauer, A. Molina, R.J. Hauke, J.A. Reeves, S. Babu, P. Van Veldhuizen, B. Somer, V. Gunuganti, I. Schnadig, S. George, R.D. Page, E. Arrowsmith, R.K. Jain, J. Zhang, M.B. McHenry, J.L. Johansen, N.J. Vogelzang, Safety and efficacy of nivolumab in patients with advanced clear cell renal cell carcinoma: results from the Phase IIIb\/IV CheckMate 374 Study. Clin. Genitourin. Cancer 18(6), 469\u2013476.e4 (2020). https:\/\/doi.org\/10.1016\/j.clgc.2020.06.002","journal-title":"Clin. Genitourin. Cancer"},{"issue":"28","key":"4050_CR55","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.21.01003","volume":"39","author":"TL Rose","year":"2021","unstructured":"T.L. Rose, M.R. Harrison, A.M. Deal, S. Ramalingam, Y.E. Whang, B. Brower, M. Dunn, C.K. Osterman, H.M. Heiling, M.A. Bjurlin, A.B. Smith, M.E. Nielsen, H.-J. Tan, E. Wallen, M.E. Woods, D. George, T. Zhang, A. Drier, W.Y. Kim, M.I. Milowsky, Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 39(28), 3140\u20133148 (2021). https:\/\/doi.org\/10.1200\/JCO.21.01003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"4050_CR56","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/dme.14050","volume":"36","author":"HK Akturk","year":"2019","unstructured":"H.K. Akturk, D. Kahramangil, A. Sarwal, L. Hoffecker, M.H. Murad, A.W. Michels, Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet. Med. A J. Br. Diabet. Assoc. 36(9), 1075\u20131081 (2019). https:\/\/doi.org\/10.1111\/dme.14050","journal-title":"Diabet. Med. A J. Br. Diabet. Assoc."},{"issue":"2","key":"4050_CR57","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11154-020-09618-w","volume":"22","author":"V Lo Preiato","year":"2021","unstructured":"V. Lo Preiato, S. Salvagni, C. Ricci, A. Ardizzoni, U. Pagotto, C. Pelusi, Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature. Rev. Endocr. Metab. Disord. 22(2), 337\u2013349 (2021). https:\/\/doi.org\/10.1007\/s11154-020-09618-w","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"6","key":"4050_CR58","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4093\/dmj.2023.0072","volume":"47","author":"YK Cho","year":"2023","unstructured":"Y.K. Cho, C.H. Jung, Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: from its molecular mechanisms to clinical practice. Diab. Metab. J. 47(6), 757\u2013766 (2023). https:\/\/doi.org\/10.4093\/dmj.2023.0072","journal-title":"Diab. Metab. J."},{"issue":"7","key":"4050_CR59","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"R.M. Ruggeri, A. Campenn\u00ec, G. Giuffrida, P. Trimboli, L. Giovanella, F. Trimarchi, S. Cannav\u00f2, Endocrine and metabolic adverse effects of immune checkpoint inhibitors: An overview (what endocrinologists should know). J. Endocrinol. Investig. 42(7), 745\u2013756 (2019). https:\/\/doi.org\/10.1007\/s40618-018-0984-z","journal-title":"J. Endocrinol. Investig."},{"issue":"8","key":"4050_CR60","doi-asserted-by":"publisher","first-page":"7630","DOI":"10.3390\/ijms24087630","volume":"24","author":"MV Deligiorgi","year":"2023","unstructured":"M.V. Deligiorgi, D.T. Trafalis, A concerted vision to advance the knowledge of diabetes mellitus related to immune checkpoint inhibitors. Int. J. Mol. Sci. 24(8), 7630 (2023). https:\/\/doi.org\/10.3390\/ijms24087630","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"4050_CR61","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1080\/14740338.2022.2134343","volume":"21","author":"DS Popovic","year":"2022","unstructured":"D.S. Popovic, T. Koufakis, B. Kovacevic, M. Rizzo, N. Papanas, Immune checkpoint inhibitors-induced diabetes mellitus: A growing clinical presentation requiring our attention. Expert Opin. Drug Saf. 21(11), 1337\u20131339 (2022). https:\/\/doi.org\/10.1080\/14740338.2022.2134343","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"4050_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemrpt.2023.100022","volume":"2","author":"NL Haas","year":"2023","unstructured":"N.L. Haas, J. Sell, B.S. Bassin, F.K. Korley, Diabetic ketoacidosis as a complication of immune checkpoint inhibitor therapy. JEM Rep. 2(2), 100022 (2023). https:\/\/doi.org\/10.1016\/j.jemrpt.2023.100022","journal-title":"JEM Rep."},{"key":"4050_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0245-2","volume":"5","author":"JL Godwin","year":"2017","unstructured":"J.L. Godwin, S. Jaggi, I. Sirisena, P. Sharda, A.D. Rao, R. Mehra, C. Veloski, Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J. Immunother. Cancer 5, 40 (2017). https:\/\/doi.org\/10.1186\/s40425-017-0245-2","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"4050_CR64","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"J.A. Thompson, B.J. Schneider, J. Brahmer, S. Andrews, P. Armand, S. Bhatia, L.E. Budde, L. Costa, M. Davies, D. Dunnington, M.S. Ernstoff, M. Frigault, B. Hoffner, C.J. Hoimes, M. Lacouture, F. Locke, M. Lunning, N.A. Mohindra, J. Naidoo, J.L. Scavone, Management of immunotherapy-related toxicities, version 1.2019. J. Natl Compr. Cancer Netw.: JNCCN 17(3), 255\u2013289 (2019). https:\/\/doi.org\/10.6004\/jnccn.2019.0013","journal-title":"J. Natl Compr. Cancer Netw.: JNCCN"},{"issue":"5","key":"4050_CR65","doi-asserted-by":"publisher","first-page":"e220513","DOI":"10.1530\/EC-22-0513","volume":"12","author":"R Percik","year":"2023","unstructured":"R. Percik, S. Criseno, S. Adam, K. Young, D.L. Morganstein, Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer. Endocr. Connect. 12(5), e220513 (2023). https:\/\/doi.org\/10.1530\/EC-22-0513","journal-title":"Endocr. Connect."},{"issue":"4","key":"4050_CR66","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15053","volume":"40","author":"K Mulla","year":"2023","unstructured":"K. Mulla, S. Farag, B. Moore, S. Matharu, K. Young, J. Larkin, S. Popat, D.L. Morganstein, Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment. Diabet. Med.: A J. Br. Diabet. Assoc. 40(4), e15053 (2023). https:\/\/doi.org\/10.1111\/dme.15053","journal-title":"Diabet. Med.: A J. Br. Diabet. Assoc."},{"issue":"4","key":"4050_CR67","first-page":"733","volume":"9","author":"WH Hoffman","year":"1988","unstructured":"W.H. Hoffman, C.M. Steinhart, T. el Gammal, S. Steele, A.R. Cuadrado, P.K. Morse, Cranial CT in children and adolescents with diabetic ketoacidosis. AJNR Am. J. Neuroradiol. 9(4), 733\u2013739 (1988)","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"1","key":"4050_CR68","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/NEJMra1404489","volume":"372","author":"RH Sterns","year":"2015","unstructured":"R.H. Sterns, Disorders of plasma sodium\u2014Causes, consequences, and correction. N. Engl. J. Med. 372(1), 55\u201365 (2015). https:\/\/doi.org\/10.1056\/NEJMra1404489","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"4050_CR69","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1007\/s00125-006-0363-8","volume":"49","author":"JA Edge","year":"2006","unstructured":"J.A. Edge, R.W. Jakes, Y. Roy, M. Hawkins, D. Winter, M.E. Ford-Adams, N.P. Murphy, A. Bergomi, B. Widmer, D.B. Dunger, The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia 49(9), 2002\u20132009 (2006). https:\/\/doi.org\/10.1007\/s00125-006-0363-8","journal-title":"Diabetologia"},{"issue":"4","key":"4050_CR70","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.metabol.2015.12.007","volume":"65","author":"EA Nyenwe","year":"2016","unstructured":"E.A. Nyenwe, A.E. Kitabchi, The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metab. Clin. Exp. 65(4), 507\u2013521 (2016). https:\/\/doi.org\/10.1016\/j.metabol.2015.12.007","journal-title":"Metab. Clin. Exp."},{"issue":"12","key":"4050_CR71","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.2337\/dc09-1431","volume":"32","author":"K Yasuda","year":"2009","unstructured":"K. Yasuda, H. Tanahashi, M. Hayashi, N. Yamakita,, Hyperglycemic crises in adult patients with diabetes. Diab. Care 32(12), e157 (2009). https:\/\/doi.org\/10.2337\/dc09-1431","journal-title":"Diab. Care"},{"issue":"7","key":"4050_CR72","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/dc09-9032","volume":"32","author":"AE Kitabchi","year":"2009","unstructured":"A.E. Kitabchi, G.E. Umpierrez, J.M. Miles, J.N. Fisher, Hyperglycemic crises in adult patients with diabetes. Diab. Care 32(7), 1335\u20131343 (2009). https:\/\/doi.org\/10.2337\/dc09-9032","journal-title":"Diab. Care"},{"key":"4050_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1213225","volume":"14","author":"M Shen","year":"2023","unstructured":"M. Shen, D. Chen, R. Zhao, X. Zheng, Y. Gu, T. Yang, Y. Shi, Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus. Front. Endocrinol. 14, 1213225 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1213225","journal-title":"Front. Endocrinol."},{"issue":"3","key":"4050_CR74","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3892\/ol.2023.13963","volume":"26","author":"M Liu","year":"2023","unstructured":"M. Liu, L. Christ, A. Richters, B.C. \u00d6zdemir, Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease. Oncol. Lett. 26(3), 377 (2023). https:\/\/doi.org\/10.3892\/ol.2023.13963","journal-title":"Oncol. Lett."},{"issue":"2","key":"4050_CR75","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"D.B. Johnson, R.J. Sullivan, P.A. Ott, M.S. Carlino, N.I. Khushalani, F. Ye, A. Guminski, I. Puzanov, D.P. Lawrence, E.I. Buchbinder, T. Mudigonda, K. Spencer, C. Bender, J. Lee, H.L. Kaufman, A.M. Menzies, J.C. Hassel, J.M. Mehnert, J.A. Sosman, J.I. Clark, Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2(2), 234\u2013240 (2016). https:\/\/doi.org\/10.1001\/jamaoncol.2015.4368","journal-title":"JAMA Oncol."},{"key":"4050_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585311","volume":"10","author":"JW Hommes","year":"2020","unstructured":"J.W. Hommes, R.J. Verheijden, K.P.M. Suijkerbuijk, D. Hamann, Biomarkers of checkpoint inhibitor induced immune-related adverse events-a comprehensive review. Front. Oncol. 10, 585311 (2020). https:\/\/doi.org\/10.3389\/fonc.2020.585311","journal-title":"Front. Oncol."},{"issue":"6","key":"4050_CR77","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1245\/s10434-023-13250-8","volume":"30","author":"T Nagano","year":"2023","unstructured":"T. Nagano, F. Kinoshita, A. Hashinokuchi, K. Matsudo, K. Watanabe, S. Takamori, M. Kohno, N. Miura, M. Shimokawa, T. Takenaka, T. Yoshizumi, Prognostic impact of C-reactive protein-to-lymphocyte ratio in non-small cell lung cancer: a propensity score-matching analysis. Ann. Surgical Oncol. 30(6), 3781\u20133788 (2023). https:\/\/doi.org\/10.1245\/s10434-023-13250-8","journal-title":"Ann. Surgical Oncol."},{"issue":"4","key":"4050_CR78","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cllc.2023.01.014","volume":"24","author":"C Azzoli","year":"2023","unstructured":"C. Azzoli, L. Huynh, D. Yi, M.S. Duh, B. Cai, Retrospective study to examine prognostic value of C-reactive protein in patients with surgically resectable non-small-cell lung cancer. Clin. Lung Cancer 24(4), 329\u2013338 (2023). https:\/\/doi.org\/10.1016\/j.cllc.2023.01.014","journal-title":"Clin. Lung Cancer"},{"issue":"10","key":"4050_CR79","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","volume":"145","author":"A-R Abolhassani","year":"2019","unstructured":"A.-R. Abolhassani, G. Schuler, M.C. Kirchberger, L. Heinzerling, C-reactive protein as an early marker of immune-related adverse events. J. Cancer Res. Clin. Oncol. 145(10), 2625\u20132631 (2019). https:\/\/doi.org\/10.1007\/s00432-019-03002-1","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"4050_CR80","unstructured":"Sapra, A., & Bhandari, P. (2024). Diabetes. In: StatPearls. StatPearls Publishing. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551501\/"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04050-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04050-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:19:55Z","timestamp":1740147595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04050-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["4050"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04050-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"16 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}